Thank you for registering your interest in our mild-to-moderate ulcerative colitis study. A member of the research team will be in touch within 2 business days to go through the study with you.
What is the study for?
This study is assessing the safety and tolerability of an experimental new treatment for mild-to-moderate ulcerative colitis, and whether this treatment can improve this condition.
The study is a Phase 1b clinical trial for people diagnosed with active mild-to-moderate ulcerative colitis.
- 9 visits to our research centre over an approximately 7.5 month period
- 3 colonoscopies with biopsy collection over this time
- 4 follow-up phone calls
- At home stool collection on multiple occasions
There are two cohorts to this study. Cohort 1 will receive study medication in an open-label fashion (i.e. participants will know which treatment they are receiving). Cohort 2 will receive study medication in a blinded and placebo-controlled fashion (i.e. participants will not know which treatment they are getting). There is a 2 in 3 chance of receiving placebo in cohort 2.
The research team will sit down with you and go through the study criteria, as well as your medical history, current and past medications and vaccinations. There will be some blood tests and medical examinations to help determine your eligibility for the study.
You will be required to present a valid form of ID at each visit.
All study procedures are at no cost to you, and you will be compensated for your time and travel expenses at $100 per visit.
Where can I find more information?
More information can be requested by contacting the research site to the right. Alternatively, the research team will be more than happy to answer any questions you may have when they call.
HREC approval: Bellberry Human Research Ethics Committee